Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 787
- Registration Number
- NCT01010061
A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01009424
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1162
- Registration Number
- NCT01007435
- Locations
- 🇺🇸
Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States
🇦🇺Royal Prince Alfred Hospital; Rheumatology, Camperdown, New South Wales, Australia
🇺🇸Ohio State University; Dept of Immunology, Columbus, Ohio, United States
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 675
- Registration Number
- NCT01006980
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT01001299
- Locations
- 🇺🇸
UCLA - School of Medicine, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital;Hematology/ Oncology, Boston, Massachusetts, United States
🇺🇸Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01000610
- Locations
- 🇹🇳
Hopital Farhat Hached; Service Rhumatologie, Sousse, Tunisia
🇹🇳Hopital La Rabta; Service Rhumatologie, Tunis, Tunisia
🇹🇳Hopital Charles Nicole; Service Rhumatologie, Tunis, Tunisia
A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT00996606
A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: DMARDs (disease-modifying antirheumatic drugs)
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 201
- Registration Number
- NCT00996203
- Locations
- 🇷🇺
Sverdlovsk Regional Clinical Hospital # 1; Rheumatology Dept, Ekaterinburg, Russian Federation
🇷🇺Republican Clinicodiagnostic Center, Izhevsk, Russian Federation
🇷🇺Kaliningrad Regional Clinical Hospital; Rheumatologic Department, Kaliningrad, Russian Federation
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 188
- Registration Number
- NCT00988221
- Locations
- 🇦🇺
Princess Margaret Children'S Hospital; Department of Immunology, Subiaco, Western Australia, Australia
🇨🇦Alberta Children'S Hospital, Calgary, Alberta, Canada
🇨🇦Children'S Hospital of Eastern Ontario, Ottawa, Ontario, Canada
A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT00988325
- Locations
- 🇩🇪
Onkologische Schwerpunktpraxis Dr. Med. O. Burkhard & B. Reimann, Worms, Germany
🇮🇹Fondazione Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
🇵🇱Vitamed, Bydgoszcz, Poland